IMPT-514 + IMPT-514 + IMPT-514

Phase 1/2Withdrawn

0 views this week 0 watching💤 Quiet

Interest: 14/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Systemic Lupus Erythematosus

Conditions

Systemic Lupus Erythematosus, Lupus Nephritis

Trial Timeline

Feb 15, 2024 → Jan 9, 2025

NCT ID

NCT06153095

About IMPT-514 + IMPT-514 + IMPT-514

IMPT-514 + IMPT-514 + IMPT-514 is a phase 1/2 stage product being developed by Lyell Immunopharma for Systemic Lupus Erythematosus. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06153095. Target conditions include Systemic Lupus Erythematosus, Lupus Nephritis.

What happened to similar drugs?

10 of 20 similar drugs in Systemic Lupus Erythematosus were approved

Approved (10) Terminated (4) Active (7)

✅Baricitinib + CyclophosphamideEli LillyApproved

✅Rosuvastatin + SimvastatinAstraZenecaApproved

✅AnifrolumabAstraZenecaApproved

✅EfalizumabMerckApproved

✅AmbrisentanGilead SciencesApproved

✅BMS-986165Bristol Myers SquibbApproved

✅versus hydroxychloroquineSanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06153095	Phase 1/2	Withdrawn	Feb 15, 2024	Jan 9, 2025	Systemic Lupus Erythematosus

Competing Products

20 competing products in Systemic Lupus Erythematosus

See all competitors

Product	Company	Stage	Hype Score
Tabalumab Auto-Injector + Tabalumab Prefilled Syringe	Eli Lilly	Phase 3	32
Baricitinib + Placebo	Eli Lilly	Phase 2	35
MRA(Tocilizumab) + placebo	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
DS-7011a + Placebo	Daiichi Sankyo	Phase 1	29
DS-7011a + Placebo	Daiichi Sankyo	Phase 1/2	32
Bocidelpar + Placebo	Astellas Pharma	Phase 1	21
Parenteral micafungin application + Other parenteral antifungal drugs	Astellas Pharma	Pre-clinical	26
Micafungin	Astellas Pharma	Phase 2	35
E6742	Eisai	Phase 1/2	32
KHK4827	Kyowa Kirin	Phase 1	29
KHK4827 + Placebo	Kyowa Kirin	Phase 3	40
Baricitinib + Placebo	Eli Lilly	Phase 3	40
Baricitinib + Cyclophosphamide	Eli Lilly	Approved	47
Baricitinib + Placebo	Eli Lilly	Phase 3	32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care	Eli Lilly	Phase 3	40
LY3361237 + Placebo	Eli Lilly	Phase 2	27
LY2127399 + Placebo	Eli Lilly	Phase 3	32
LY3361237 + Placebo	Eli Lilly	Phase 1	29